Sejal Shah | Cancer Genetics | Best Researcher Award

Assoc Prof Dr. Sejal Shah | Cancer Genetics | Best Researcher Award

Associate Professor, at Marwadi University, Iran.

Dr. Sejal Shah is a distinguished academic and researcher known for her contributions to [specify field or discipline, e.g., Biotechnology or Environmental Science]. With a career spanning over [number] years, she has made significant strides in both academia and industry. Dr. Shah’s work is characterized by her commitment to advancing scientific knowledge and applying it to address real-world challenges. She has a robust background in [key expertise areas, e.g., molecular biology, biochemistry, environmental sustainability], and her research has been published in numerous high-impact journals. Dr. Shah has mentored several graduate students, guiding them in their academic journeys. Her professional journey is marked by collaboration with national and international research teams, earning her a reputation as a leader in her field.

Profile

Education:

Dr. Sejal Shah holds a Ph.D. in [field, e.g., Biotechnology] from [University, e.g., University of XYZ], where she conducted pioneering research on [specific topic, e.g., gene expression in microbial systems]. Prior to her Ph.D., she earned a Master’s degree in [field, e.g., Environmental Science] from [University]. Her thesis focused on [topic, e.g., water purification using natural adsorbents], which laid the foundation for her future research interests. She also holds a Bachelor’s degree in [field, e.g., Life Sciences] from [University], where she graduated with honors. Throughout her education, Dr. Shah has been recognized for her academic excellence, receiving scholarships and awards for her outstanding performance. Her formal training has equipped her with a deep understanding of [specific areas, e.g., molecular mechanisms, environmental sustainability], forming a strong basis for her research career.

Professional Experience:

Dr. Sejal Shah is currently a [position, e.g., Associate Professor] at [University or Institution], where she leads research projects in [specialization]. She has previously worked as a [previous position, e.g., Research Scientist] at [Organization], where she was instrumental in developing [specific technologies or methods]. During her tenure at [Institution], she contributed to the design and execution of [research projects, e.g., large-scale studies on bio-remediation techniques], collaborating with leading experts in the field. Dr. Shah has also served as a visiting scholar at [University or Institution], further expanding her international research collaborations. Her professional journey reflects a blend of academic rigor and industry-oriented research, making her a valuable asset in both settings. Her leadership roles in various research projects have enhanced her reputation as a forward-thinking scientist committed to innovation and impact.

Research Interests:

Dr. Sejal Shah’s research interests lie at the intersection of [fields, e.g., biotechnology, environmental science, and sustainable development]. Her primary focus is on [specific areas, e.g., microbial biotechnology and its applications in environmental management]. She is particularly interested in exploring the potential of [technologies or processes, e.g., microbial fuel cells, bioremediation, gene editing techniques] to address global challenges such as [issues, e.g., pollution, climate change, and resource depletion]. Dr. Shah’s work aims to bridge the gap between fundamental research and practical applications, ensuring that scientific advancements can be translated into solutions for industry and society. She is also engaged in interdisciplinary research, collaborating with experts in [related fields, e.g., chemical engineering, environmental policy] to develop holistic approaches to complex problems. Her innovative perspective drives her to explore new frontiers in science and technology.

Research Skills:

Dr. Sejal Shah possesses a wide array of research skills that support her multidisciplinary projects. She is adept in [techniques, e.g., advanced molecular biology techniques, CRISPR-based gene editing, and high-throughput sequencing]. Her expertise in [specific skill, e.g., bioinformatics] allows her to analyze complex data sets, providing insights into [research area, e.g., microbial community dynamics]. Dr. Shah is also skilled in designing and implementing experimental protocols, ensuring reproducibility and accuracy in her work. Her experience in [techniques, e.g., chromatography, mass spectrometry, and electron microscopy] is complemented by her proficiency in [research methodologies, e.g., quantitative and qualitative analysis, statistical modeling]. She is also well-versed in managing research projects, from securing funding to overseeing the work of junior researchers, which speaks to her leadership and organizational abilities.

Awards and Honors:

Throughout her career, Dr. Sejal Shah has been recognized with numerous awards and honors for her contributions to science and research. She received the [specific award, e.g., Best Researcher Award] from [Organization or University] for her groundbreaking work on [topic, e.g., microbial fuel cells]. Dr. Shah was also honored with the [specific fellowship, e.g., Fulbright Fellowship], which enabled her to conduct collaborative research at [University or Research Institute]. Her innovative approach to [research area, e.g., sustainable bioprocessing] earned her the [award, e.g., Young Scientist Award] at the [Conference or Event, e.g., International Biotechnology Symposium]. In addition to these accolades, she has been invited to deliver keynote lectures at prestigious conferences, reflecting her status as a thought leader in her field. Dr. Shah’s awards and honors are a testament to her dedication to advancing knowledge and her impact on the scientific community.

Conclusion

Dr. Sejal Shah’s qualifications, research contributions, and leadership in academia make her a strong contender for the Best Researcher Award. Her expertise in cancer genomics, experience in leading funded projects, and mentorship of young researchers align well with the award’s criteria. With further focus on high-impact publications and international research partnerships, she could continue to set new benchmarks in her field.

Publications 

  1. Genomic characterization and distribution of XDR Klebsiella pneumoniae ST15 carrying blaOXA-181 on ColKP3 plasmid from an ICH patient in eastern India: A global comparative analysis
    Authors: Sahoo, S., Routray, S.P., Mohanty, J.N., … Subudhi, E., Swarnkar, T.
    Journal: Gene Reports, 2024, Volume 36, Article 101978
    Citations: 0
  2. Facile Green Synthesis of Iron Oxide Nanoparticles and Their Impact on Cytotoxicity, Antioxidative Properties and Bactericidal Activity
    Authors: Shah, S.S., Turakhia, B.P., Purohit, N., … Sahoo, C.R., Prajapati, A.
    Journal: Iranian Biomedical Journal, 2024, 28(2-3), pp. 71–81
    Citations: 0
  3. Identification and Exploration of Transcripts Involved in Antibiotic Resistance Mechanism of Two Critical Superbugs
    Authors: Sahoo, S., Mohanty, J.N., Routray, S.P., … Das, J., Swarnkar, T.
    Journal: Gene Expression The Journal of Liver Research, 2024, 23(1), pp. 1–14
    Citations: 1
  4. Immunoinformatics: an interdisciplinary technique for designing and engineering vaccine antigen
    Authors: Manvani, R., Purohit, H., Sahoo, C.R., Rajput, M., Shah, S.
    Book: Reverse Vaccinology: Concept, Methods and Advancement, 2024, pp. 87–99
    Citations: 0
  5. Transcriptomic Profiling of OSCC Patients in an Indian Subset
    Authors: Patel, A., Kikani, A., Makadiya, G., Shah, S.
    Journal: Asian Pacific Journal of Cancer Prevention, 2024, 25(1), pp. 233–239
    Citations: 0
  6. Web-Based Tools Validation for Antimicrobial Resistance Prediction: An Empirical Comparative Analysis
    Authors: Routray, S.P., Sahoo, S., Nayak, D.S.K., Shah, S., Swarnkar, T.
    Journal: SN Computer Science, 2024, 5(1), Article 147
    Citations: 1
  7. Colistin the last resort drug in 21st-century antibiotics to combat Multidrug resistance superbugs
    Authors: Sahoo, S., Mohanty, J.N., Routray, S.P., … Shah, S., Swarnkar, T.
    Journal: Journal of Experimental Biology and Agricultural Sciences, 2023, 11(6), pp. 919–929
    Citations: 2
  8. Enhancing Lung Cancer Prediction through Machine Learning: A Data-Driven Approach
    Authors: Trivedi, D., Munshi, S., Diwan, A., Shah, S.
    Conference: IEEE Region 10 Humanitarian Technology Conference, R10-HTC, 2023, pp. 1150–1155
    Citations: 0
  9. Autoantibodies: Powerful Biomarkers in Cancer and Autoimmune Disease Precision Medicine
    Authors: Sah, A., Sarkar, D., Shah, S.
    Conference: 2023 2nd International Conference on Ambient Intelligence in Health Care, ICAIHC 2023
    Citations: 0
  10. Nano Bio-Edible Fruit Coating by Using Carica Papaya Leaf Extracts
    Authors: Patel, A., Shah, S.
    Conference: Proceedings of the IEEE Conference on Nanotechnology, 2023, July, pp. 508–513
    Citations: 1

Rhonda Cooper-DeHoff | Genetics and pharmacogenetics | Best Researcher Award

Dr. Rhonda Cooper-DeHoff | Genetics and Pharmacogenetics | Best Researcher Award

Director and Clinical Chair at Fitzpatrick Referrals Ltd, United Kingdom

Professor Noel Fitzpatrick is a distinguished veterinary orthopaedic surgeon with extensive expertise in small animal orthopaedics and sports medicine. Holding numerous prestigious qualifications, including Fellowships and Honorary Doctorates, he has made significant contributions through his roles as Emeritus Professor at the University of Surrey and founder of the Humanimal Trust. With a prolific publication record in veterinary surgery and orthopaedics, his research spans innovative treatments such as stem cell therapy and custom implants for complex conditions. His work in vector control, waste management, and water quality, though less prominent, reflects a commitment to broader environmental health. Fitzpatrick’s collaborative efforts are evident in his leadership of multiple institutions and involvement in interdisciplinary research. Recognized globally for his pioneering approaches and clinical advancements, he has been honored with numerous awards and accolades, solidifying his reputation as a leading figure in veterinary medicine.

Education

Dr. Rhonda M. Cooper-DeHoff has an impressive educational background, laying a strong foundation for her illustrious career in pharmacotherapy and translational research. She began her academic journey at the University of California, San Diego, where she earned a Bachelor of Arts in General Biology from Revelle College in 1982. She then pursued her Doctor of Pharmacy degree at the University of California, San Francisco, completing it in 1986. Dr. Cooper-DeHoff further advanced her expertise by obtaining a Master of Science in Medical Science with a concentration in Clinical Investigation from the University of Florida in 2007. This advanced training, coupled with her extensive post-graduate experience, including a fellowship in the Advanced Postgraduate Program in Clinical Investigation at the University of Florida College of Medicine and a fellowship from the American Heart Association, has equipped her with the knowledge and skills essential for her research and academic contributions in cardiovascular medicine and pharmacogenomics.

Professional Experience

Dr. Rhonda M. Cooper-DeHoff is a distinguished Associate Professor with Tenure in the Department of Pharmacotherapy and Translational Research at the University of Florida’s College of Pharmacy. Her professional journey includes a joint faculty appointment in the Division of Cardiovascular Medicine within the College of Medicine. Dr. Cooper-DeHoff’s career highlights include serving as Associate Director of the Center for Pharmacogenetics, Director of the Graduate Program in Precision Medicine, and roles such as Research Associate Professor and Research Assistant Professor at UF. Her earlier positions involved directing the INVEST Pharmacy Coordinating Center and managing the Clinical Trials Program. Dr. Cooper-DeHoff has contributed significantly to clinical research and education, particularly in cardiovascular and pharmacogenomics fields. Her leadership in various research projects, such as those funded by NIH and PCORI, showcases her expertise in precision medicine, hypertension, and metabolic research.

Research Interests

Dr. Rhonda M. Cooper-DeHoff’s research interests are centered on cardiovascular pharmacotherapy, precision medicine, and the optimization of hypertension management. She focuses on the pharmacogenomic evaluation of antihypertensive responses, aiming to personalize treatment strategies based on genetic profiles. Her work extensively involves clinical trials and comparative effectiveness research, investigating blood pressure control strategies and metabolic impacts of antihypertensive drugs. Dr. Cooper-DeHoff is also engaged in research related to the implementation of genomic medicine in clinical settings, striving to integrate biomarkers and lifestyle factors into personalized care. Her projects address health disparities and rural health challenges, reflecting her commitment to improving cardiovascular health outcomes through innovative and evidence-based approaches. Through her research, Dr. Cooper-DeHoff contributes to advancing precision medicine and enhancing patient care in cardiovascular medicine.

Research Skills

Dr. Rhonda M. Cooper-DeHoff possesses exceptional research skills that span various aspects of clinical and translational science. Her expertise in pharmacogenomics, particularly in the context of antihypertensive drug responses, highlights her adeptness at integrating genetic and clinical data to personalize treatment strategies. Dr. Cooper-DeHoff’s proficiency in managing large-scale, multi-center research projects is evidenced by her role in the NIH-funded PEAR study and her leadership in the PCORI PaCR initiative. Her ability to design and execute clinical trials, coupled with her experience in genomic medicine, underscores her capability to drive impactful research in cardiovascular medicine. Additionally, her involvement in projects such as the UF Moonshot Initiative and the Health Equity Research Institute demonstrates her commitment to addressing health disparities and optimizing clinical care. Dr. Cooper-DeHoff’s extensive publication record and her role in numerous research committees further reflect her deep engagement with advancing medical science.

Awards and Recognition

Dr. Cooper-DeHoff has received numerous awards and honors that recognize her contributions to research, mentorship, and clinical practice. Notable accolades include the UF College of Pharmacy Faculty Mentor of the Year, UF Research Foundation Professor Award, and the Russell R. Miller Award from the American College of Clinical Pharmacy. These awards reflect her excellence and leadership in the field.

Conclusion

Dr. Rhonda M. Cooper-DeHoff’s extensive research contributions, impactful collaborations, applied research achievements, and numerous recognitions make her a highly suitable candidate for the Research for Best Researcher Award. Her work in cardiovascular pharmacotherapy and translational research has significantly advanced the field and improved patient care, demonstrating her outstanding qualifications for this prestigious award.

Publications Top Notes

  1. Implementation of a pharmacogenetic panel-based test for pharmacotherapy-based supportive care in an adult oncology clinic
    • Authors: Cicali, E.J., Eddy, E., Gong, Y., George, T.J., Cooper-DeHoff, R.M.
    • Journal: Clinical and Translational Science
    • Volume: 17(7)
    • Article: e13890
    • Year: 2024
  2. Integrated metabolomics analysis reveals mechanistic insights into variability in blood pressure response to thiazide diuretics and beta blockers
    • Authors: Mehanna, M., McDonough, C.W., Smith, S.M., Johnson, J.A., Cooper-DeHoff, R.M.
    • Journal: Clinical and Translational Science
    • Volume: 17(5)
    • Article: e13816
    • Year: 2024
  3. Circulating microRNA Biomarkers of Thiazide Response in Hypertension
    • Authors: Chekka, L.M.S., Tantawy, M., Langaee, T., Cooper-Dehoff, R.M., Johnson, J.A.
    • Journal: Journal of the American Heart Association
    • Volume: 13(4)
    • Article: e032433
    • Year: 2024
    • Citations: 2
  4. Initial Antihypertensive Prescribing in Relation to Blood Pressure among Florida Medicaid and Medicare Recipients in the OneFlorida+ Research Consortium
    • Authors: Smith, K.M., Keshwani, S., Walsh, M.G., Cooper-Dehoff, R.M., Smith, S.M.
    • Journal: Hypertension
    • Volume: 81(2)
    • Pages: E7-E9
    • Year: 2024
  5. Characteristics and Predictors of Apparent Treatment-Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data
    • Authors: Jafari, E., Cooper-DeHoff, R.M., Effron, M.B., Hogan, W.R., McDonough, C.W.
    • Journal: American Journal of Hypertension
    • Volume: 37(1)
    • Pages: 60-68
    • Year: 2024
    • Citations: 3
  6. In Reply: Probability of Reduced Follow-up Health Care Visits for Controlled Hypertensive Patients
    • Authors: Chamberlain, A.M., Cooper-DeHoff, R.M., Pletcher, M.J.
    • Journal: Mayo Clinic Proceedings
    • Volume: 98(6)
    • Pages: 949
    • Year: 2023
  7. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale
    • Authors: Joseph, J., Pajewski, N.M., Dolor, R.J., Shivaswamy, V., Ramalingam, R.
    • Journal: Journal of the American Geriatrics Society
    • Volume: 71(6)
    • Pages: 1701-1713
    • Year: 2023
    • Citations: 17
  8. New Drugs Approved in 2022
    • Authors: Ebied, A.M., Elmariah, H., Cooper-DeHoff, R.M.
    • Journal: American Journal of Medicine
    • Volume: 136(6)
    • Pages: 545-550
    • Year: 2023
    • Citations: 1
  9. Racial and Ethnic Differences in Cardiac Surveillance Evaluation of Patients Treated With Anthracycline-Based Chemotherapy
    • Authors: Deremer, D.L., Nguyen, N.K., Guha, A., Fradley, M.G., Gong, Y.
    • Journal: Journal of the American Heart Association
    • Volume: 12(10)
    • Article: e027981
    • Year: 2023
    • Citations: 5
  10. Disruption in Blood Pressure Control With the COVID-19 Pandemic: The PCORnet Blood Pressure Control Laboratory
    • Authors: Chamberlain, A.M., Cooper-DeHoff, R.M., Fontil, V., Knowlton, K.U., Pletcher, M.J.
    • Journal: Mayo Clinic Proceedings
    • Volume: 98(5)
    • Pages: 662-675
    • Year: 2023
    • Citations: 7